OOIR: Observatory of International Research

Papers

(The TQCC of Pharmacological Reviews is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Seventy-Five Years of Interactions: The Department of Physiology and Pharmacology at Karolinska Institutet and Pharmacological Reviews	351
The Role of G Protein–Coupled Receptors and Receptor Kinases in Pancreatic β-Cell Function and Diabetes	334
Innovative therapeutics for renoprotection: Where we are	216
Neurobiological Mechanisms of Nicotine Reward and Aversion	147
The Myc Family and the Metastasis Suppressor NDRG1: Targeting Key Molecular Interactions with Innovative Therapeutics	133
Review of Natural Language Processing in Pharmacology	128
The Nitrogen Mustards	127
Carbonic anhydrase inhibitors: “Old” drugs with new potential in unexpected areas	125
Therapeutic advantage of combinatorial chimeric antigen receptor T cell and chemotherapies	124
Table of Contents	115
Table of Contents	106
Metal-based antibody, nanobody, and peptide conjugates: Potential for breast cancer therapy	95
The endocannabinoidomes: Pharmacological redundancy and promiscuity, and multi-kingdom variety of sources and molecular targets	93
Table of Contents	88
Sex Differences in Opioid and Psychostimulant Craving and Relapse: A Critical Review	86
Elucidating the Interactome of G Protein-Coupled Receptors and Receptor Activity-Modifying Proteins	85
International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily—Update 2023	83
Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer	81
Pharmaceutical perspectives on oligonucleotide therapeutics and delivery systems	81
Innovation in cancer pharmacotherapy through integrative consideration of germline and tumor genomes	78
Table of Contents	77
Optical Approaches for Investigating Neuromodulation and G Protein–Coupled Receptor Signaling	77
Asthma therapeutics: Past, present, and future	77
Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease	64
G Protein-Coupled Receptor Pharmacology—Insights from Mass Spectrometry	64

Therapeutic Potential of Targeting Prokineticin Receptors in Diseases	61
Roles of Individual Human Cytochrome P450 Enzymes in Drug Metabolism	60
Molecular Tweezers: Supramolecular Hosts with Broad-Spectrum Biological Applications	58
Carbon Monoxide Signaling: Examining Its Engagement with Various Molecular Targets in the Context of Binding Affinity, Concentration, and Biologic Response	57
The Hippo pathway: Organ size control and beyond	52
Corrigendum to “International Union of Basic and Clinical Pharmacology. CXIX. Fundamental insights and clinical relevance regarding the carnitine palmitoyltransferase family of enzymes” [Pharmacologic	51
Targeting Persistent Changes in Neuroimmune and Epigenetic Signaling in Adolescent Drinking to Treat Alcohol Use Disorder in Adulthood	51
Nonhormonal Male Contraceptive Development—Strategies for Progress	50
Sulfotransferase 2B1b, Sterol Sulfonation, and Disease	49
Opportunities for Nitric Oxide in Potentiating Cancer Immunotherapy	48
Neurobiology of the incubation of drug craving: An update	46
Dopamine, Immunity, and Disease	44
Editorial Board	44
Pharmacological Reviews’ 75th Year Anniversary: Past and Future—Editorial	43
Targeting Systemic Innate Immune Cells as a Therapeutic Avenue for Alzheimer Disease	42
Extracellular Vesicle Heterogeneity and Its Impact for Regenerative Medicine Applications	41
Animal Behavior in Psychedelic Research	38
Heme-thiolate monooxygenase cytochrome P450 1B1, an old dog with many new tricks	37
Conotoxins Targeting Voltage-Gated Sodium Ion Channels	36
Vitamin D and its analogs in immune system regulation	34
Effects of Medications on Heat Loss Capacity in Chronic Disease Patients: Health Implications Amidst Global Warming	33
Post-Traumatic Epilepsy and Comorbidities: Advanced Models, Molecular Mechanisms, Biomarkers, and Novel Therapeutic Interventions	33
Somatostatin: Linking Cognition and Alzheimer Disease to Therapeutic Targeting	32
Pharmacological strategies to bridge the gap between cancer and cardiovascular therapeutics	31
Table of Contents	31
The Development of Cannabinoids as Therapeutic Agents in the United States	30
Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines	30
International Union of Basic and Clinical Pharmacology. CXVIII. Update on the nomenclature for atypical chemokine receptors, including ACKR5	29
Erratum to “Advances and challenges in experimental models of posttraumatic epilepsy for therapeutic interventions” [Pharmacological Reviews 77 (2025) 100080]	27
Harnessing multiomics technologies and machine learning for advancing personalized theranostic approaches in atherosclerosis	27
Time to Change: A Systems Pharmacology Approach to Disentangle Mechanisms of Drug-Induced Mitochondrial Toxicity	26
Table of Contents	26
Potassium Channels in Parkinson’s Disease: Potential Roles in Its Pathogenesis and Innovative Molecular Targets for Treatment	26
Drugging dancing protein clouds: A close look at disorder-based drug design	26
Table of Contents	25
The complement system: Biology, pathology, and therapeutic interventions	25
Anticoagulants: From chance discovery to structure-based design	24
α6-Containing GABAA Receptors: Functional Roles and Therapeutic Potentials	24
Development of small molecule inhibitors of hypoxia-inducible factors for cancer therapy	24